Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.
Chastre J., François B., Bourgeois M., Komnos A., Ferrer R., Rahav G., De Schryver N., Lepape A., Koksal I., Luyt C.E. et al., 2022/11/15. Critical care, 26 (1) p. 355. Peer-reviewed.
ici le détail